Screening for hemochromatosis: A public health perspective

American Journal of Preventive Medicine

Volumn 16, Issue 2, 1999, Pages 134-140

  Cogswell, Mary E ^a   Burke, Wylie ^b   McDonnell, Sharon M ^a   Franks, Adele L ^a  

^a And Office of the Director ^*  (United States)

^b Natl Ctr Chron Dis Prev H   (United States)

Author keywords

Chronic disease; Diagnosis; Genetic screening; Hemochromatosis; Iron; Preventive medicine

Indexed keywords

ARTICLE; CANCER RISK; CHRONIC DISEASE; DNA DETERMINATION; EARLY DIAGNOSIS; GENETIC ANALYSIS; GENETIC SCREENING; HEMOCHROMATOSIS; HUMAN; PROGNOSIS; PUBLIC HEALTH; SCREENING;

GENETICS AND REPRODUCTION; HEALTH CARE AND PUBLIC HEALTH;

COST OF ILLNESS; ETHICS, MEDICAL; GENETIC SCREENING; HEALTH POLICY; HEMOCHROMATOSIS; HUMANS; PENETRANCE; PHLEBOTOMY; PREVALENCE; PUBLIC HEALTH PRACTICE; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TRANSFERRIN; UNITED STATES;

EID: 0033063831     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-3797(98)00141-X     Document Type: Article

References (73)

1. Troisier M. Diabete sucre. Bull Soc Anat Paris. 44:1871;231-235.
2. von Reckinghausen FD. Taggeblat der (62) Versammiling Deutsche Naturforscher und Artze im Heidelberg. 1889:324-5.
3. Witte D.L., Crosby W.H., Edwards C.Q., Fairbanks V.F., Mitros F.A. Practice Guideline Development Task Force of the College of American Pathologists Hereditary hemochromatosis . Clin Chim Acta. 245:1996;139-200.
4. Sheldon J.H. Haemochromatosis. 1935;235-305 Oxford University Press, London.
5. Simon M., Pawlotsky Y., Bourel M., Fauchet J., Genetet B. Hemochromatose idiopathique maladie associee a l'antigene tissulaire HL-A3? Nouv Presse Med. 4:1975;1432.
6. Simon M., Bourel M., Genetet B., Fauchet R. Idiopathic hemochromatosis demonstration of recessive transmission and early detection by family HLA typing . N Engl J Med. 297:1977;1017-1021.
7. Feder J.N., Gnirk A., Thomas W., et al. A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis. Nat Genet. 13:1996;399-408.
8. Mercier B., Mura L., Ferer L. Putting a hold on HLA-H. Nat Genet. 15:1997;234-235.
9. Feder J.N., Penny D.M., Irrinki A., et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci. 95:1998;1472-1477.
10. Cogswell M.E., McDonnell S.M., Khoury M.J., Franks A.L., Burke W., Brittenham G. Iron overload, public health and genetics evaluating the evidence for hemochromatosis screening . Annals of Internal Medicine. 129:1998;971-979.
11. Adams P.C., Valberg L.S. Evolving expression of hereditary hemochromatosis. Semin Liver Dis. 16:1996;47-54.
12. Niederau C., Fischer R., Purschel A., et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 110:1996;1107-1119.
13. Adams P.C., Deugnier Y., Moirand R., Brissot P. The relationship between iron overload, clinical symptoms and age in 410 hemochromatosis patients. Hepatology. 25:1997;162-166.
14. Phatak P.D., Guzman G., Woll J.E., Robeson A., Phelps C.E. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 154:1994;769-776.
15. Edwards C.Q., Kushner J.P. Screening for hemochromatosis. N Engl J Med. 328:1993;1616-1620.
16. Buffone G.J., Beck R.J. Cost-effectiveness analysis for evaluation of screening programs hereditary hemochromatosis . Clin Chem. 40:1994;1631-1636.
17. Haddow J.E., Ledue T.B. Preventing manifestations of hereditary hemochromatosis through population based screening. J Med Screen. 1:1994;16-21.
18. Lederle F.A. Screening for hemochromatosis. J Gen Intern Med. 4:1989;61-63.
19. Bradley L.A., Haddow J.E., Palomaki G.E. Population screening for haemochromatosis Expectations based on a study of relatives of symptomatic probands . J Med Screen. 3:1996;171-177.
20. Bassett M.L., Halliday J.W., Bryant S., Dent O., Powell L.W. Screening for hemochromatosis. Ann NY Acad Sci. 526:1988;274-289.
21. Pippard MJ. Secondary iron overload. In: Iron metabolism in health and disease. Brock JH, Halliday JW, Pippard MJ, Powell LW, editors. Philadelphia: W.B. Saunders Co., 1994;271-309.
22. Powell L.W., George D.K., McDonnell S.M., Kowdley K.V. Diagnosis of hemochromatosis. Ann of Intern Med. 129:1998;925-931.
23. Kowdley K.V., Trainer T.D., Saltzman J.R., et al. Utility of hepatic iron index in American patients with hereditary hemochromatosis A multicenter study . Gastroenterology. 113:1997;1270-1277.
24. Adams P.C., Bradley C., Henderson A.R. Evaluation of the hepatic iron index as a diagnostic criterion for genetic hemochromatosis. J Lab Clin Med. 130:1997;509-514.
25. Halliday J.W., Searle J. Hepatic iron deposition in human disease and animal models. Biometals. 9:1996;205-209.
26. Bradley L.A., Haddow J.E., Palomaki G.E. Population screening for haemochromatosis a unifying analysis of published intervention trials . J Med Screen. 3:1996;178-184.
27. McDonnell S.M., Phatak P., Felliti V., Hover A., McLaren G.D. Screening for hemochromatosis in primary care settings. Ann Intern Med. 129:1998;962-970.
28. Iron overload disorders among Hispanics - San Diego, California, 1995. MMWR. 45:1996;991-993.
29. Edwards C.Q., Griffen L.M., Goldgar D., Drummond C., Skolnick M.H., Kushner J.P. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med. 318:1988;1355-1362.
30. Neiderau C., Niederau C.M., Lange S., et al. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med. 128:1998;337-345.
31. Phatak P.D., Sham R.L., Raubertas R.F., et al. Prevalence of hereditary hemochromatosis in a sample of 16,031 primary care patients. Ann Intern Med. 129:1998;954-961.
32. Hsieh C.-L., Sutton H.E. Mitochondrial and nuclear variants in a U.S. Black population: origins of a hybrid population. Ann Hum Genet. 50:1992;145-155.
33. Chakraborty R., Kamboh M.I., Nwanko M., Ferrell R.E. Caucasian genes in American Blacks new data . Am J Hum Genet. 50:1992;145-155.
34. Gayle C.B. Hemochromatosis and dietary iron supplementation implications from US mortality, morbidity and health survey data . J Am Diet Assoc. 92:1992;208-212.
35. Yang Q., McDonnell S.M., Khoury M.J., Cono J., Parrish G. Hemochromatosis mortality in the United States, 1979-92 an analysis of multiple cause mortality data . Ann Intern Med. 129:1998;946-953.
36. Olynyk J., Hall P., Ahern M., Kwiatek R., Mackinnon M. Screening for genetic haemochromatosis in a rheumatology clinic. Aust N Z J Med. 24:1994;588-589.
37. George D.K., Evans R.M., Crofton R.W., Gunn I.R. Testing for haemochromatosis in the diabetic clinic. Ann Clin Biochem. 32:1995;521-526.
38. Guide to Clinical Preventive Services, 2nd ed. 1996;231-246 Williams & Wilkins, Baltimore, MD.
39. Recommendations to prevent and control iron deficiency in the United States. MMWR. 47:(RR-3):1998;1-29.
40. Burke W., Thomson E., Khoury M., et al. Hereditary hemochromatosis gene discovery and its implications for population-based screening . JAMA. 280:1998;172-178.
41. Carella M., D'Ambrosio L., Totaro A., et al. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet. 60:1997;828-832.
42. Beutler E., Gelbart T., West C., et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis. 22:1996;187-194.
43. Jouanolle A.M., Gandon G., Jezequel P., et al. Hemochromatosis and HLA-H. Nat Genet. 14:1996;251-252.
44. Barton J.C., Shih W.W.H., Sawada-Hirai R., et al. Genetic and clinical description of hemochromatosis probands and heterozygotes evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis . Blood Cells Mol Dis. 23:1997;135-145.
45. Borot N., Roth M.-P., Malfroy L., et al. Mutations in the MHC1-like candidate gene for hemochromatosis in French patients. Immunogenetics. 45:1997;320-324.
46. A simple genetic test identifies 90 percent of UK patients with haemochromatosis. Gut. 41:1997;841-844.
47. Adams P.C., Campion M.L., Gandon G., LeGAll J.Y., David V. Jouanolle AM. Clinical and family studies in genetic hemochromatosis. Microsatellite and HFE studies in five atypical families. Hepatology. 26:1997;986-990.
48. Jazwinska E.C., Cullen L.M., Busfield F., et al. Hemochromatosis and HLA-H. Nat Genet. 13:1996;399-408.
49. Beutler E., Gelbart T. HLA-H mutations in the Ashkenazi Jewish population. Blood Cell Mol Dis. 23:1997;95-98.
50. Merryweather-Clarke A.T., Pointon J.J., Shearman J.D., Robson K.J.H. Global prevalence of putative haemochromatosis mutations. J Med Genet. 34:1997;275-278.
51. Crawford D.H.G., Jazwinska E.C., Cullen L.M., Powell L.M. Expression of HLA-l linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology. 114:1998;1003-1008.
52. Barton J.C., McDonnell S.M., Adams P.C., et al. Management of hemochromatosis. Ann Intern Med. 129:1998;932-939.
53. Tobkes A.I., Nord H.J. Liver biopsy Review of methodology and complications . Dig Dis. 13:1995;267-274.
54. Finch S.C., Finch C.A. Idiopathic hemochromatosis An iron storage disease . Medicine (Baltimore). 34:1955;381-430.
55. Adams P.C., Speechley M., Kertesz A.E. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology. 101:1991;368-372.
56. Fargion S., Mandelli C., Piperno A., et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology. 15:1992;655-659.
57. Bomford A., Williams R. Long term results of venesection therapy in idiopathic hemochromatosis. Q J Med. 45:1976;611-623.
58. Launois B., Chauvin J., Machado M.L., Bourdonnec P., Campion J.P., Bardaxoglou E. Surgical treatment of hepatocarcinoma in cirrhosis. Ann Gastroenterol Hepatol. 32:1996;35-39.
59. Stuart K.E., Anand A.J., Jenkins R.L. Hepatocellular carcinoma in the United States. Cancer. 77:1996;2217-2222.
60. Bellantini S., Tiribelli C., Saccoccio G., et al. Prevalence of chronic liver disease in the general population of Northern Italy the Dionysos Study . Hepatology. 20:1994;1442-1449.
61. Bell H., Skinningsrud A., Raknerud N., Try K. Serum ferritin and transferrin saturation in patients with chronic alcoholic and non-alcoholic liver diseases. J Intern Med. 236:1994;315-322.
62. Piperno A., D'Alba R., Fargion S., et al. Liver iron concentration in chronic viral hepatitis a study of 98 patients . Eur J Gastroenterol Hepatol. 7:1995;1203-1208.
63. Rosenqvist M., Hultcrantz R. Prevalence of haemochromatosis among men with clinically significant bradyarrythmias. Eur Heart J. 10:1989;473-478.
64. Conte D., Mananchino D., Colli A., et al. Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Ann Intern Med. 128:1998;370-373.
65. Manachino D., Andrea G., Ottinetti A., Martinotti R. Hemochromatosis and diabetes. Mayo Clin Proc. 69:1994;913.
66. Czink E., Tamas G. Screening for idiopathic haemochromatosis among diabetic patients. Diabetes Care. 14:1991;929-930.
67. O'Brien T., Barrett B., Murray D.M., Dinneen S., O'Sullivan D.J. Usefulness of biochemical screening of diabetic patients for hemochromatosis. Diabetes Care. 13:1990;532-534.
68. Phelps G., Chapman I., Hall P., Braund W., MacKinnon M. Prevalence of genetic haemochromatosis among diabetic patients. Lancet. 2:1989;233-234.
69. Institute of Medicine. Assessing Genetic Risks: Implications For Health and Social Policy. Washington, DC: National Academy Press; 1994.
70. Khoury M.J. From genes to public health the applications of genetic technology in disease prevention . Am J Public Health. 86:1996;1717-1722.
71. Alper J.S., Geller L.N., Barash C.I., Billings P.R., Laden V., Natowicz M.R. Genetic discrimination and screening for hemochromatosis. J Public Health Policy. 15:1994;345-358.
72. Brittenham G.M., Franks A.L., Rickles F.R. Research priority in hereditary hemochromatosis. Ann Intern Med. 129:1998;993-996.
73. Recommendations for the use of folic acid to reduce the number of cases of spina bifada and other neural tube defects. MMWR. 41:(RR-14):1992;1-13.